20/20 GeneSystems has launched its Clinical Lab Innovation Axcellerator (CLIAx), believed to be the first shared CLIA laboratory facility geared to helping diagnostic test innovators worldwide substantially reduce the time and cost of launching their tests in the U.S.
“Establishing and maintaining a compliant CLIA lab can be costly and daunting for young companies, especially those seeking to enter the American market from overseas,” 20/20 President and CEO, Jonathan Cohen said.“From leasing facilities to hiring qualified laboratory professionals, purchasing equipment, and running daily operations, it can be a hefty burden.
“These hurdles can limit or delay our nation’s access to some of the most creative and out-of-the- box testing solutions from around the world demonstrated during the pandemic to be in great demand. Our unique CLIA Axcellerator removes or lowers many of the barriers in the path of these innovators.”
CLIAx offers nearly 3,000 square feet of readyto-use communal clinical laboratory space and testing equipment, including a full PCR/molecular assaysuite,NextGenSequencing(NGS),immunoassay, and clinical chemistry capabilities. Importantly, 20/20’s marketing and sales teams will help promote the new tests introduced by CLIAx’s clients to the market segments in which 20/20 is currently active.